Valeant Looks Better to Bondholders After Botox
This article is for subscribers only.
A shot of Botox is making Valeant Pharmaceuticals International Inc. more attractive to bondholders already.
With his $45.7 billion bid for Allergan Inc., Valeant Chief Executive Officer Mike Pearson is pulling the credit rating of Canada’s most indebted junk bond issuer closer to investment grade while attempting the biggest takeover in the country’s history.